http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 27 Jul 2026 17:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+27/26820454.html si-local-file:///var/storage/secattach/20260727/26820454.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+27/26820454.html Mon, 27 Jul 2026 17:06:00 -0400 CODX O.29488102 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+27/26820454.html si-local-file:///var/storage/secattach/20260727/26820454.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+27/26820454.html Mon, 27 Jul 2026 17:06:00 -0400 CODX O.29488102 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Co-Diagnostics%2C+Inc.+++++++++++++++++/26820432.html si-local-file:///var/storage/secattach/20260727/26820432.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Co-Diagnostics%2C+Inc.+++++++++++++++++/26820432.html Mon, 27 Jul 2026 17:03:00 -0400 CODX O.29488102 http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Co-Diagnostics%2C+Inc.+++++++++++++++++/26820432.html si-local-file:///var/storage/secattach/20260727/26820432.html http://www.streetinsider.com/SEC+Filings/Form++424B5++++++Co-Diagnostics%2C+Inc.+++++++++++++++++/26820432.html Mon, 27 Jul 2026 17:03:00 -0400 CODX O.29488102 http://www.streetinsider.com/Corporate+News/CoSara+starts+TB+clinical+trials+in+India+using+Co-Diagnostics+PCR+tech/26799147.html <p>Co-Diagnostics, Inc. (Nasdaq: CODX) announced that CoSara Diagnostics Pvt. Ltd., its joint venture in India, has initiated clinical studies for a tuberculosis test using the CoSara PCR Pro instrument.</p> <p>The CoSara PCR Pro instrument, a CoSara-branded version of the Co-Dx PCR Pro point-of-care device, is being deployed to select laboratories across India for tuberculosis testing evaluation. The platform uses Co-Diagnostics' patented Co-Primers technology and is designed to deliver real-time PCR results in approximately 30 minutes via a mobile application.</p> <p>PCR Pro instruments, mycobacterium tuberculosis test kits, and proprietary sample preparation instruments have been shipped to CoSara. Co-Dx PCR platform products, including test http://www.streetinsider.com/Corporate+News/CoSara+starts+TB+clinical+trials+in+India+using+Co-Diagnostics+PCR+tech/26799147.html Wed, 22 Jul 2026 09:00:43 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/Corporate+News/CoSara+starts+TB+clinical+trials+in+India+using+Co-Diagnostics+PCR+tech/26799147.html <p>Co-Diagnostics, Inc. (Nasdaq: CODX) announced that CoSara Diagnostics Pvt. Ltd., its joint venture in India, has initiated clinical studies for a tuberculosis test using the CoSara PCR Pro instrument.</p> <p>The CoSara PCR Pro instrument, a CoSara-branded version of the Co-Dx PCR Pro point-of-care device, is being deployed to select laboratories across India for tuberculosis testing evaluation. The platform uses Co-Diagnostics' patented Co-Primers technology and is designed to deliver real-time PCR results in approximately 30 minutes via a mobile application.</p> <p>PCR Pro instruments, mycobacterium tuberculosis test kits, and proprietary sample preparation instruments have been shipped to CoSara. Co-Dx PCR platform products, including test http://www.streetinsider.com/Corporate+News/CoSara+starts+TB+clinical+trials+in+India+using+Co-Diagnostics+PCR+tech/26799147.html Wed, 22 Jul 2026 09:00:43 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/Corporate+News/CoSara+starts+TB+clinical+trials+in+India+using+Co-Diagnostics+PCR+tech/26799147.html <p>Co-Diagnostics, Inc. (Nasdaq: CODX) announced that CoSara Diagnostics Pvt. Ltd., its joint venture in India, has initiated clinical studies for a tuberculosis test using the CoSara PCR Pro instrument.</p> <p>The CoSara PCR Pro instrument, a CoSara-branded version of the Co-Dx PCR Pro point-of-care device, is being deployed to select laboratories across India for tuberculosis testing evaluation. The platform uses Co-Diagnostics' patented Co-Primers technology and is designed to deliver real-time PCR results in approximately 30 minutes via a mobile application.</p> <p>PCR Pro instruments, mycobacterium tuberculosis test kits, and proprietary sample preparation instruments have been shipped to CoSara. Co-Dx PCR platform products, including test http://www.streetinsider.com/Corporate+News/CoSara+starts+TB+clinical+trials+in+India+using+Co-Diagnostics+PCR+tech/26799147.html Wed, 22 Jul 2026 09:00:43 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/Corporate+News/CoSara+starts+TB+clinical+trials+in+India+using+Co-Diagnostics+PCR+tech/26799147.html <p>Co-Diagnostics, Inc. (Nasdaq: CODX) announced that CoSara Diagnostics Pvt. Ltd., its joint venture in India, has initiated clinical studies for a tuberculosis test using the CoSara PCR Pro instrument.</p> <p>The CoSara PCR Pro instrument, a CoSara-branded version of the Co-Dx PCR Pro point-of-care device, is being deployed to select laboratories across India for tuberculosis testing evaluation. The platform uses Co-Diagnostics' patented Co-Primers technology and is designed to deliver real-time PCR results in approximately 30 minutes via a mobile application.</p> <p>PCR Pro instruments, mycobacterium tuberculosis test kits, and proprietary sample preparation instruments have been shipped to CoSara. Co-Dx PCR platform products, including test http://www.streetinsider.com/Corporate+News/CoSara+starts+TB+clinical+trials+in+India+using+Co-Diagnostics+PCR+tech/26799147.html Wed, 22 Jul 2026 09:00:43 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html <div class="xn-content"> <p class="prntac"><i>PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4736364-1&amp;h=1217086153&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that <span>CoSara Diagnostics Pvt. Ltd.</span> ("CoSara"), the Company's joint venture in <location value="LC/in" idsrc="xmltag.org" >India</location>, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro<b>^®</b> instrument.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html Wed, 22 Jul 2026 09:00:00 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html <div class="xn-content"> <p class="prntac"><i>PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4736364-1&amp;h=1217086153&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that <span>CoSara Diagnostics Pvt. Ltd.</span> ("CoSara"), the Company's joint venture in <location value="LC/in" idsrc="xmltag.org" >India</location>, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro<b>^®</b> instrument.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html Wed, 22 Jul 2026 09:00:00 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html <div class="xn-content"> <p class="prntac"><i>PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4736364-1&amp;h=1217086153&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that <span>CoSara Diagnostics Pvt. Ltd.</span> ("CoSara"), the Company's joint venture in <location value="LC/in" idsrc="xmltag.org" >India</location>, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro<b>^®</b> instrument.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html Wed, 22 Jul 2026 09:00:00 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html <div class="xn-content"> <p class="prntac"><i>PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4736364-1&amp;h=1217086153&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that <span>CoSara Diagnostics Pvt. Ltd.</span> ("CoSara"), the Company's joint venture in <location value="LC/in" idsrc="xmltag.org" >India</location>, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro<b>^®</b> instrument.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html Wed, 22 Jul 2026 09:00:00 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html <div class="xn-content"> <p class="prntac"><i>PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4736364-1&amp;h=1217086153&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that <span>CoSara Diagnostics Pvt. Ltd.</span> ("CoSara"), the Company's joint venture in <location value="LC/in" idsrc="xmltag.org" >India</location>, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro<b>^®</b> instrument.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html Wed, 22 Jul 2026 09:00:00 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html <div class="xn-content"> <p class="prntac"><i>PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4736364-1&amp;h=1217086153&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that <span>CoSara Diagnostics Pvt. Ltd.</span> ("CoSara"), the Company's joint venture in <location value="LC/in" idsrc="xmltag.org" >India</location>, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro<b>^®</b> instrument.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html Wed, 22 Jul 2026 09:00:00 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html <div class="xn-content"> <p class="prntac"><i>PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4736364-1&amp;h=1217086153&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that <span>CoSara Diagnostics Pvt. Ltd.</span> ("CoSara"), the Company's joint venture in <location value="LC/in" idsrc="xmltag.org" >India</location>, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro<b>^®</b> instrument.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html Wed, 22 Jul 2026 09:00:00 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html <div class="xn-content"> <p class="prntac"><i>PCR Pro Instruments and MTB Test Kits Now Deployed to Select Labs Across India</i></p><p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 22, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4736364-1&amp;h=1217086153&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that <span>CoSara Diagnostics Pvt. Ltd.</span> ("CoSara"), the Company's joint venture in <location value="LC/in" idsrc="xmltag.org" >India</location>, is initiating clinical studies for the tuberculosis test on the CoSara PCR Pro<b>^®</b> instrument.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Co-Diagnostics+Joint+Venture+CoSara+Initiates+Clinical+Studies+in+India+for+Tuberculosis+Test+on+PCR+Platform/26799133.html Wed, 22 Jul 2026 09:00:00 -0400 A.06822034 CODX O.20026344 O.29488102 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+21/26793248.html si-local-file:///var/storage/secattach/20260721/26793248.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+21/26793248.html Tue, 21 Jul 2026 09:00:00 -0400 CODX O.29488102 http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+21/26793248.html si-local-file:///var/storage/secattach/20260721/26793248.html http://www.streetinsider.com/SEC+Filings/Form++DEF+14A++++Co-Diagnostics%2C+Inc.++++++For%3A+Jul+21/26793248.html Tue, 21 Jul 2026 09:00:00 -0400 CODX O.29488102 http://www.streetinsider.com/Corporate+News/Co-Diagnostics+names+Wes+Lindsey+as+chief+scientific+officer/26777474.html <p>Co-Diagnostics, Inc. (Nasdaq: CODX) has appointed Wes Lindsey, PhD, MBA as its new Chief Scientific Officer, the Salt Lake City-based molecular diagnostics company announced.</p><p>Dr. Lindsey holds a PhD in Genetics and Molecular Biology from Emory University and an MBA from Georgia State University. He brings more than 20 years of experience in molecular diagnostics, including leading assay development and R&D teams that produced more than a dozen FDA 510(k) submissions and CE-marked assays for in vitro diagnostic products.</p><p>"Wes brings two decades of experience building and leading molecular diagnostics teams through FDA clearance, including point-of-care and near-point-of-care IVDs, and that expertise http://www.streetinsider.com/Corporate+News/Co-Diagnostics+names+Wes+Lindsey+as+chief+scientific+officer/26777474.html Thu, 16 Jul 2026 09:01:10 -0400 CODX http://www.streetinsider.com/Management+Changes/Co-Diagnostics+names+Wes+Lindsey+as+chief+scientific+officer/26777474.html <p>Co-Diagnostics, Inc. (Nasdaq: CODX) has appointed Wes Lindsey, PhD, MBA as its new Chief Scientific Officer, the Salt Lake City-based molecular diagnostics company announced.</p><p>Dr. Lindsey holds a PhD in Genetics and Molecular Biology from Emory University and an MBA from Georgia State University. He brings more than 20 years of experience in molecular diagnostics, including leading assay development and R&D teams that produced more than a dozen FDA 510(k) submissions and CE-marked assays for in vitro diagnostic products.</p><p>"Wes brings two decades of experience building and leading molecular diagnostics teams through FDA clearance, including point-of-care and near-point-of-care IVDs, and that expertise http://www.streetinsider.com/Management+Changes/Co-Diagnostics+names+Wes+Lindsey+as+chief+scientific+officer/26777474.html Thu, 16 Jul 2026 09:01:10 -0400 CODX http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4733034-1&amp;h=3913365370&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4733034-1&amp;h=3913365370&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4733034-1&amp;h=3913365370&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4733034-1&amp;h=3913365370&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679 http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ut.sltlkc" idsrc="xmltag.org" >SALT LAKE CITY</location></span>, <span class="legendSpanClass"><chron>July 16, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4733034-1&amp;h=3913365370&amp;u=https%3A%2F%2Fco-dx.com%2F&amp;a=Co-Diagnostics%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:CODX" idsrc="xmltag.org" >Co-Diagnostics, Inc.</span></a><b> (Nasdaq: CODX)</b> ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the appointment of <person>Wes Lindsey</person>, PhD, MBA as the Company's new Chief Scientific Officer ("CSO").</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> <p> http://www.streetinsider.com/Press+Releases/Co-Diagnostics+Appoints+Wes+Lindsey%2C+PhD%2C+MBA+as+Chief+Scientific+Officer/26777413.html Thu, 16 Jul 2026 09:00:00 -0400 A.01412971 A.29114199 CODX O.03960701 O.29488102 O.48402679